Gene
RET
RET is a gene biomarker in the evidence tier "FDA companion diagnostic". This page lists evidence by type: FDA companion diagnostic assertions (6), Assay-provider ledger (87), Actionable biomarkers (14), and 7 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
2 more sections with rows · 2 sections measured, none recorded
FDA companion diagnostic
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention RET. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers. Not plotted: 4 with a planned future start and 6 with no date at all.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 36 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 81 of 8,738 | 0.93% | not measured | |
| 2025 | 84 of 8,875 | 0.95% | not measured | |
| 2024 | 67 of 8,597 | 0.78% | not measured | |
| 2023 | 66 of 8,275 | 0.80% | 108 of 11,460 | 0.94% |
| 2022 | 54 of 8,285 | 0.65% | 122 of 13,598 | 0.90% |
| 2021 | 49 of 8,692 | 0.56% | 134 of 15,045 | 0.89% |
| 2020 | 33 of 7,640 | 0.43% | 118 of 14,459 | 0.82% |
| 2019 | 16 of 7,300 | 0.22% | 97 of 12,159 | 0.80% |
| 2018 | 22 of 6,927 | 0.32% | 86 of 11,854 | 0.73% |
| 2017 | 24 of 6,558 | 0.37% | 87 of 11,595 | 0.75% |
Showing 10 of 37 years.
FDA companion diagnostic assertions (6)
Shown in this order: most recent decision first.
| Diagnostic | Source biomarker wording | Manufacturer | Indication | Decision date |
|---|---|---|---|---|
| TruSight Oncology Comprehensive | RET | Illumina, Inc. | Non-Small Cell Lung Cancer (NSCLC) | 2024-08-21 |
| FoundationOne CDx | RET | Foundation Medicine, Inc. | Solid Tumors | 2023-10-06 |
| Oncomine Dx Target Test | RET | Life Technologies Corporation | Thyroid Cancer (TC) | 2022-09-21 |
| Oncomine Dx Target Test | RET | Life Technologies Corporation | Medullary Thyroid Cancer (MTC) | 2022-09-21 |
| Oncomine Dx Target Test | RET | Life Technologies Corporation | Non-Small Cell Lung Cancer (NSCLC) | 2022-09-21 |
Showing 5 of 6 companion diagnostic entries.
Assay-provider ledger (87)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Illumina | Unclassified | Clinical validationAnalytical validation | 10 | April 22, 2026 +1 undated |
| QIAGEN | Reagent supplier | Clinical validationAnalytical validation | 5 | April 22, 2026 |
| AmoyDx | Diagnostic provider | Clinical validationAnalytical validation | 1 | December 08, 2025 |
| Horizon | Reagent supplier | Clinical validationAnalytical validation | 1 | December 08, 2025 |
| ROCHE | Context dependent | Clinical validationAnalytical validation | 2 | December 08, 2025 |
Showing 5 of 87 assay-provider companies.
Actionable biomarkers (14)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| RET fusion | Ret Inhibitors | response-associated | lung adenocarcinoma | Cancer Genome Interpreter |
| RET fusion | Nintedanib | response-associated | lung adenocarcinoma | Cancer Genome Interpreter |
| RET fusion | CABOZANTINIB | response-associated | lung adenocarcinoma | Cancer Genome Interpreter |
| RET fusion | Vandetanib | response-associated | lung adenocarcinoma | Cancer Genome Interpreter |
| RET fusion | SUNITINIB | response-associated | lung adenocarcinoma | Cancer Genome Interpreter |
Showing 5 of 14 actionable-biomarker assertions.
Trial mentions (631)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT06639191 | Trial eligibility (AACT) |
| NCT05581706 | Trial eligibility (AACT) |
| NCT07566052 | Trial eligibility (AACT) |
| NCT07068542 | Trial eligibility (AACT) |
| NCT05617313 | Trial eligibility (AACT) |
Showing 5 of 631 trial mentions.
Target-disease associations (1,002)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 17q12 microdeletion syndrome | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| 46,XX disorder of sex development - anorectal anomalies | cancer or benign tumor | Mouse knockout (IMPC) |
| 46,XX ovotesticular disorder of sex development | endocrine system disease | Mouse knockout (IMPC) |
| 46,XY complete gonadal dysgenesis | cardiovascular disease | Mouse knockout (IMPC) |
| 46,XY disorder of sex development due to 17-beta-hydroxysteroid dehydrogenase 3 deficiency | endocrine system disease | Mouse knockout (IMPC) |
Showing 5 of 1,002 associations.
Vendor sourcing (1,996)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The variant is not observed in the gnomAD v2.1.1 dataset. Predicted Consequence/Location: Missense variant In silico tool predictions suggest damaging effect... | View ClinVar record SCV005903771.1 |
| ANRS, Emerging Infectious Diseases | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : * Patient infected with HIV-1 and not co-infected with HIV-2 * Age ≥ 18 at enrollment * Able to give written consent * Covered by French Social Security *... | View trial NCT01520844 |
| ANRS, Emerging Infectious Diseases | Trial sponsor | Mentioned in trial textTrial free-text mention | PTC | View trial NCT01520844 |
| AOU S.Orsola Malpighi-Unit of Oncologic Molecular and Transplantations Pathology | Trial collaborator | Exploratory endpoint in a trialTrial endpoint | RET aberration | View trial NCT04131543 |
| AOU S.Orsola Malpighi-Unit of Oncologic Molecular and Transplantations Pathology | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : 1. Locally advanced, relapsed or metastatic non-small cell lung cancer - stage IIIB/IV according to 7th International Association for the Study of Lung Ca... | View trial NCT04131543 |
Showing 5 of 1,996 sourcing records.
Trial-cited literature (1,317)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Improving aerobic capacity in patients with advanced non-small cell lung cancer: study protocol of the 3-armed randomized controlled BREATH trial. | Trials | 2026 | 0 |
| Hepatocellular carcinoma: signaling pathways and therapeutic advances. | Signal transduction and targeted therapy | 2025 | 291 |
| Selpercatinib in <i>RET</i> Fusion-Positive Non-Small Cell Lung Cancer: Final Safety and Efficacy, Including Overall Survival, From the LIBRETTO-001 Phase I/II Trial. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2025 | 27 |
| Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial. | The Lancet. Oncology | 2025 | 18 |
| Clinical Activity of Selpercatinib in RET-mutant Pheochromocytoma. | The Journal of clinical endocrinology and metabolism | 2025 | 14 |
Showing 5 of 1,317 papers.
Protein variant mentions (154)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A1020V | 1 | 2015 | PMID 25741868 |
| p.A1105V | 1 | 2015 | PMID 25741868 |
| p.A496V | 1 | 2015 | PMID 25741868 |
| p.A510V | 2 | 2015 | PMID 25741868, PMID 26580448 |
| p.A604V | 1 | 2015 | PMID 25741868 |
Showing 5 of 154 variants.
Literature-extracted relations (326)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| SUNITINIB | Chemical | negative_correlate |
Sunitinib as Second-Line Treatment in Advanced Intrahepatic Cholangiocarcinoma: Results From the SUN-CK GERCOR Phase II Trial. | 2025 |
| Erlotinib | Chemical | negative_correlate |
A phase II trial of gemcitabine and erlotinib followed by ChemoProton therapy plus capecitabine and oxaliplatin for locally advanced pancreatic cancer. | 2022 |
| SUNITINIB | Chemical | negative_correlate |
Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma. | 2022 |
| Itraconazole | Chemical | negative_correlate |
Itraconazole Exerts Its Antitumor Effect in Esophageal Cancer By Suppressing the HER2/AKT Signaling Pathway. | 2021 |
| Oxygen | Chemical | associate |
The effect of intermittent hypoxic exposure on erythropoietic response and hematological variables in elite athletes. | 2020 |
Showing 5 of 326 relation assertions.
Organizations publishing (794)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | Hospital | 94 | 2002 to 2024 |
| The University of Texas System | Academic | 78 | 2004 to 2025 |
| Dana-Farber Cancer Institute | Other | 69 | 1996 to 2023 |
| Government of the United States of America | Government | 69 | 2001 to 2023 |
| Mass General Brigham | Hospital | 57 | 2001 to 2025 |
Showing 5 of 794 organizations.
Where RET appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- infectious disease
- integumentary system disease
- measurement
- nervous system disease
- nutritional or metabolic disease
- phenotype
- reproductive system or breast disease
- urinary system disease
834 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda biomarker qualification projects and human sample screening reference.